Linac-based hypofractionated stereotactic radiotherapy for metastases involving the brainstem

•Hypofractionated stereotactic radiotherapy (hSRT) is an option for treatment of metastases intrinsic to or abutting the brainstem.•We have treated patients with 5 fraction regimens with doses ranging from 20 Gy to 31.25 Gy.•Tumor control rate, survival rate and toxicity profiles were excellent.•In our series, hSRT resulted in similar rates of survival, tumor control and toxicities compared with published single fraction series.